Exodus Point Capital Management, LP Zentalis Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$17.41 - $30.05 $978,128 - $1.69 Million	-56,182 Reduced 75.32%	18,410 $519,000
Q1 2023 May 11, 2023	SELL	$16.14 - $24.94 $178,395 - $275,661	-11,053 Reduced 12.91%	74,592 $1.28 Million
Q4 2022 Feb 13, 2023	SELL	$18.07 - $25.6 $1.31 Million - $1.85 Million	-72,324 Reduced 45.78%	85,645 $1.73 Million
Q3 2022 Nov 10, 2022	BUY	$20.23 - $31.73 $3.2 Million - $5.01 Million	157,969 New	157,969 $3.42 Million
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $248,199 - $389,550	-5,300 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $198,272 - $329,925	5,300 New	5,300 $282,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $170M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.